KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Shares Outstanding (2016 - 2025)

Eli Lilly's Shares Outstanding history spans 17 years, with the latest figure at $944.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding changed 0.33% year-over-year to $944.8 million; the TTM value through Dec 2025 reached $944.8 million, changed 0.33%, while the annual FY2025 figure was $944.8 million, 0.33% changed from the prior year.
  • Shares Outstanding reached $944.8 million in Q4 2025 per LLY's latest filing, roughly flat from $946.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $959.5 million in Q1 2021 to a low of $944.8 million in Q4 2025.
  • Average Shares Outstanding over 5 years is $950.7 million, with a median of $950.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: soared 196417.04% in 2021, then fell 0.93% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $954.1 million in 2021, then dropped by 0.37% to $950.6 million in 2022, then dropped by 0.08% to $949.8 million in 2023, then dropped by 0.2% to $947.9 million in 2024, then decreased by 0.33% to $944.8 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's Shares Outstanding are $944.8 million (Q4 2025), $946.2 million (Q3 2025), and $947.2 million (Q2 2025).